Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
...Also expect to announce additional revenue contracts.
09/08, 2017
http://ih.advfn.com/p.php?pid=nmona&article=75612791
...imo - GM is a done deal
why: I met with Chrysler Corporation Yesterday and they asked us to make some specific changes to our software. I spoke with our developers and this change will happen within 30 days. After the change we will set up a follow up meeting and determine how to implement our FMS safe driving APP into Chrysler vehicles."
09/01, 2017
http://ih.advfn.com/p.php?pid=nmona&article=75567135
...it`s not a split, it`s a reduction of OS
OTCQB
The Venture Market
For early-stage and developing U.S. and international companies that are not yet able to qualify for OTCQX.
To be eligible, companies must be current in their reporting and undergo an annual verification and management certification process.
Companies must meet $0.01 bid test and may not be in bankruptcy.
New May 18, 2017
Companies that follow the Alternative Reporting Standard can now qualify for OTCQB.
These companies would be required to make public disclosure available pursuant to the Alternative Reporting Standard Disclosure Guidelines for OTCQX and OTCQB and meet certain Corporate Governance requirements.
OTCQB Key Highlights
- Grouped with other companies that have audited financials available and are current in their reporting
- Minimum bid price test of $0.01 removes companies that are most likely to be the subject of dilutive stock fraud schemes and promotion
- Improved investor confidence through verified information, confirming that the Company Profile displayed on www.otcmarkets.com is current and complete
- Annual management certification process to verify officers, directors, controlling shareholders, and shares outstanding
- Greater information availability for investors through the OTC Disclosure & News Service
- Transparent prices for investors through full-depth of book with Real Time Level 2 quotes
- Access to Morningstar quantitative equity ratings and research enables investors to better analyze and benchmark a company relative to its sector
Followers: 777
what do you mean?
the next ONE is out of the woods...
...if we get an ENTERPRISE-update
“Our_next_big_focus_after_Asia_and_the_North_America_will_be_on_the_large_European_Auto_makers.”
( 09/21, 2017 : http://ih.advfn.com/p.php?pid=nmona&article=75487861 )
ON4 COMMUNICATIONS TO MEET WITH BMW AT ITS CORPORATE HEADQUARTERS IN MUNICH GERMANY ON SEPTEMBER 15 2017
http://ih.advfn.com/p.php?pid=nmona&article=75554123
New York, New York--(Marketwired June 26 2017 On4 Communications, Inc. (OTC Pink: (OTC :ONCI)) - On4 Communications (OTC: ONCI) today announced it will meet with BMW on September 15 2017 at its Corporate Headquarters in Munich Germany.
CEO Steve Berman states, This will be the first of many meetings with the European auto makers. Distracted driving has become an epidemic worldwide. BMW a pioneer in car safety understands that they need to protect consumers in everyway while driving one of their Automobiles.
As previously stated I will be in Europe the week of September 7 to meet with our App designers to finalize the beta testing of our 5 new Apps which will reach the market by 4th quarter 2017. The 5 new apps will be varied. 2 will be in Auto safety, 2 will be in the Sports Gaming industry and 1 will be MJ related. These new Apps will fall under the FMS division of Hexagon Holdings Corporation and will create 5 new streams of revenues for Hexagon Holdings Corp. We have been working on these new apps for the last year and I am pleased to say we are finally there.
ON4 COMMUNICATIONS LANDS MEETING WITH ENTERPRISE RENT A CAR
New York, NY -- August 17, 2017 -- InvestorsHub NewsWire -- On4 Communications, Inc. (OTC Pink:ONCI) today announced it has landed a meeting with Enterprise rent a car for not only its FMS Safe Driving App but also for its Mobile Tracking Device which will be available for sale on Tuesday September 5. This meeting will take place at Enterprise HQ in St Louis Missouri on Wednesday September 6 2017.
CEO Steve Berman states “Enterprise represents an entirely new market for us which is the Billion dollar rent a car business.
http://ih.advfn.com/p.php?pid=nmona&article=75471763
ON4 COMMUNICATIONS LANDS MEETING WITH ENTERPRISE RENT A CAR
New York, NY -- August 17, 2017 -- InvestorsHub NewsWire -- On4 Communications, Inc. (OTC Pink:ONCI) today announced it has landed a meeting with Enterprise rent a car for not only its FMS Safe Driving App but also for its Mobile Tracking Device which will be available for sale on Tuesday September 5. This meeting will take place at Enterprise HQ in St Louis Missouri on Wednesday September 6 2017.
CEO Steve Berman states “Enterprise represents an entirely new market for us which is the Billion dollar rent a car business.
http://ih.advfn.com/p.php?pid=nmona&article=75471763
only $0.0033 and ONCI is above $0.01
OTC alternative reporting with audited financials
http://www.otcmarkets.com/stock/ONCI/profile
...therefore no 8-k's !
http://www.otcmarkets.com/financialReportViewer?symbol=ONCI&id=174624
So where we will open & end at tuesday?
yep - awesome!
SL fishing ??
...read stickies!
maybe the MJ joint venture?
Thanks for your DD and keep us informed....
it`s toast !!
Can we take it to it's fair value ??
420JobSearch.com and ZipRecruiter.com Announce Partnership, Broadening Jobs Offered
http://ih.advfn.com/p.php?pid=nmona&article=75461386&symbol=MCIG
August 16, 2017 08:00 ET
HENDERSON, NV--(NewMediaWire - Aug 16, 2017) - mCig, Inc. (OTCQB: MCIG), a diversified company servicing the legal cannabis and vape markets with innovative products, technologies, and services is pleased to announce a partnership between its Job Search Portal (420JobSearch.com) and ZipRecruiter.com. 420jobsearch.com recently entered into an agreement with ziprecruiter.com to enable both companies to broaden the scope of jobs available to job seekers.
mCig's 420JobSearch is considered one of the largest job and recruitment sites in the cannabis industry, with leading job boards for employers, job seekers and recruiters. The website has been featured recently on various media outlets, including ABC 23 News, reported by Nazy Javid @nazyjavidnews. Video:
so the freaks are out - and MYDX can grow up.
imho
Twitter @cannabics1 (Cannabics Phamaceuticals)
Israel could become major exporter of medical marijuana https://t.co/RLbhCRinLe
— CNBX Pharmaceuticals (@CNBXPharma) August 14, 2017
Updates today on our previously announced INVITATIONS ! $ONCI
Updates today on our previously announced INVITATIONS !$ONCI
— On4 Communications (@on4company) August 14, 2017
As promised Colorado domicile update and another large government opportunity today $ONCI
— On4 Communications (@on4company) August 10, 2017
Twitter @cannabics1 (Cannabics Phamaceuticals)
https://twitter.com/cannabics1/status/894981792440168448
http://Investorideas.com - WanaCaps Launches Class Specific Options $cnbx http://www.investorideas.com/news/2017/marijuana/08071WanaCaps.asp#.WYn8SwsZw8c.twitter …
11:01 - 8. Aug. 2017
$MYDX WW outside of channel. Bullish pivots are 005 & 006 key break spots pic.twitter.com/4U26zwjAxh
— Matt_Knows (@Flex__Trades) August 8, 2017
MyDx Reviews
https://www.cdxlife.com/reviews/
MyDx Analyzer: A Cannabis Testing Lab That Can Fit in Your Back Pocket
https://www.leafly.com/news/science-tech/cannabis-home-testing-lab-mydx-analyzer
To date, the Company has sold approximately $1,500,000 in worldwide sales of the MyDx Handheld Chemical Analyzer along with the CannaDx Sensor.
$MyDx CEO @DanielYazbeck featured on @torontolife for the #MyDx analyzer!
07/21/17
Twitter @MyDxLife
$MyDx CEO @DanielYazbeck featured on @torontolife for the #MyDx analyzer! https://t.co/njeVt16f39
— MyDx (@MyDxLife) July 21, 2017
About Precipio
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, visit www.precipiodx.com.
http://www.otcmarkets.com/stock/PRPO/news/Precipio-Diagnostics-and-Transgenomic-Complete-Merger?id=163609&b=y
New Colombia Resources would also like to announce their auditors have informed them to expect their first SEC filings to be ready this week, if all goes well.
The Company is very committed to being SEC compliant.
https://finance.yahoo.com/news/colombia-resources-announces-sannabis-granted-123000442.html
Transgenomic Prepares for Planned Relisting On NASDAQ
Jun 21, 2017
http://www.otcmarkets.com/stock/TBIOD/news/Transgenomic-Prepares-for-Planned-Relisting-On-NASDAQ?id=162663&b=y
Transgenomic Inc. (OTCQB:TBIOD) today announced that it is advancing its previously announced plans for relisting on the NASDAQ Capital Market. After receiving shareholder approval, the company implemented a reverse split of its shares on June 13, 2017, in order to meet NASDAQ relisting requirements of a closing share price at or above $4.00 for five consecutive trading days. Other relisting requirements involve shareholder equity. Upon the completion of the merger between Transgenomic and Precipio Diagnostics, which is expected to occur in the next few days, the companies believe that the combined entity will satisfy the NASDAQ relisting requirements.
Paul Kinnon, President and CEO of Transgenomic, said, “The management teams of the two merger partners have been working diligently together with NASDAQ representatives with the goal of immediate relisting upon the closing.”
Ilan Danieli, CEO of Precipio, said, “We view relisting on NASDAQ as an essential step in our strategy to leverage the complementary strengths of our combined companies to achieve sustained and substantial growth. We believe that the post-merger company, which will be known as Precipio, will be well-positioned to build a leadership position in the rapidly expanding new global markets for liquid biopsy and precision medicine.”
About Transgenomic
Transgenomic Inc. is a global biotechnology company advancing personalized medicine in oncology and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCR, which enables use of liquid biopsies for mutation detection. The company also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes.
About Precipio Diagnostics
Precipio Diagnostics has built a platform to harness the intellect, expertise and technology developed within academia, delivering quality diagnostic information to physicians and patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, and its experience delivering quality service, Precipio Diagnostics offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, visit precipiodx.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements,” which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views regarding the relisting of its common stock on NASDAQ, and views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets, expectations regarding new clients, projects and prospects to accelerate the Company’s growth and generate revenue. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170621005492/en/
Copyright © 2017 Businesswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Precipio and Transgenomic Announce Experts from Yale and Harvard Joining New Scientific Advisory Board to Support Merged Company’s Growth Initiatives
Jun 16, 2017
http://www.otcmarkets.com/stock/TBIOD/news/Precipio-and-Transgenomic-Announce-Experts-from-Yale-and-Harvard-Joining-New-Scientific-Advisory-Board-to-Support-Merged-Company-rsquo-s-Growth-Initiatives?id=162291&b=y
Precipio Diagnostics and Transgenomic, Inc. (OTCQB: TBIOD) today announced the formation of a new Scientific Advisory Board (SAB) in anticipation of their previously disclosed merger. The new SAB, which will become effective on the closing of the merger, is being established to provide scientific and technical guidance and expertise to the combined company’s management and board of directors in support of current and future business initiatives. SAB members include Dr. Jeffrey Sklar of the Yale University School of Medicine, Dr. Mike Makrigiorgos of Harvard Medical School and the Dana-Farber Cancer Institute, and Dr. Gil Mor of the Yale University School of Medicine.
SAB Chair Jeffrey Sklar, MD, PhD, is a Professor of Pathology and Laboratory Medicine and Director of the Molecular Diagnostics Research Program at the Yale School of Medicine. He is a pioneer in the field of molecular diagnostics and is responsible for many innovations and discoveries related to cancer diagnostics. Dr. Sklar has also served as a scientific advisor and director at a number of biotechnology companies. He received his MD and PhD degrees from Yale and completed a residency in pathology and a post-doctoral fellowship at Stanford University, where he also served as an Associate Professor. Previously, Dr. Sklar was a Professor of Pathology at Harvard Medical School.
“The Precipio model provides significant value to all constituents, by facilitating the interaction between academic institutions, physicians and their patients, to deliver much needed quality diagnostics,” said Dr. Sklar. “Academia has a tremendous wealth of knowledge and expertise and is also in the forefront of developing advanced technologies, particularly in the area of molecular diagnostics. Precipio has demonstrated successfully its ability to capitalize on those strengths and deliver them to the market in an efficient manner. I look forward to working with the management team and the board to help advance the company’s mission.”
Mike Makrigiorgos, PhD, is Professor at Harvard Medical School and the Dana-Farber Cancer Institute. Among his many discoveries, Dr. Makrigiorgos is the inventor of the ICE COLD-PCR (ICP) technology licensed exclusively to Transgenomic. ICP is an ultra-high sensitivity DNA amplification technology that enables accurate detection of genetic mutations from either tissue or non-invasive patient samples such as blood or urine. Dr. Makrigiorgos will advise on scientific and technical issues to enhance the company’s strategy for the further adoption of ICP in the liquid biopsy market, as well as its use in medical applications beyond cancer. Dr. Makrigiorgos holds a PhD in medical physics from the University of Leeds in the UK and completed post-doctoral training at Harvard Medical School.
“I am happy to join Precipio’s Scientific Advisory Board and help the company further develop ICE-COLD PCR, a technology we originally developed at Dana-Farber,” said Dr. Makrigiorgos. “I believe Precipio will be able to play a significant role in the liquid biopsy field by offering tests that balance the clinically meaningful information obtained with the cost and effort involved.”
Gil Mor, MD, PhD, is Professor of Obstetrics, Gynecology and Reproductive Sciences and Director of the Division of Reproductive Sciences at the Yale School of Medicine. He also serves as Director of the Reproductive Immunology Unit and the Discovery to Cure translational research program. Dr. Mor will be assisting the company in exploring the application of ICP and other diagnostic technologies in conditions outside the cancer field. Professor Mor earned MS and MD degrees from the Hebrew University and a PhD from the Weizmann Institute of Science in Israel.
“I believe ICP may have broad applications beyond the important role it plays in the liquid biopsy cancer market, and I am excited to help the company explore some of those applications,” said Professor Mor. “The company’s platform provides a tremendous and unique opportunity to leverage scientific expertise within academia and to commercialize it in a meaningful way.”
Ilan Danieli, CEO of Precipio Diagnostics, said, “The key to a company’s success lies not only in its vision and products but also with the team that will execute on the vision. The new members of our Scientific Advisory Board add deep and diverse scientific expertise to complement the skills of our management team and our incoming board of directors. With their help we will be refining our strategy for existing markets, as well as evaluating new markets to grow our business. I am delighted to have these prominent scientific experts as part of our team.”
Earlier this week, Transgenomic reported that the European Patent Office (EPO) has indicated its intention to grant patent protection in Europe for the Multiplexed ICE COLD-PCR technology exclusively licensed to the Transgenomic.
Paul Kinnon, President and CEO of Transgenomic, commented, “The new SAB members from Yale and Harvard bring outstanding scientific knowledge and insight to the combined company. The recent news that the EPO has indicated its intention to grant a patent covering Multiplexed ICE COLD-PCR in Europe reinforces our belief that ICP has the potential to be both a commercial success and a transformative genomics technology for cancer and other conditions, as the utility of liquid biopsies drives wide use and precision medicine increasingly becomes the norm. It is tremendous to have Mike Makrigiorgos, the father of ICP, on board, along with the deep expertise and varied perspectives of Dr. Sklar and Dr. Mor, both highly respected researchers and practitioners with a wealth of relevant experience.”
Separately, Transgenomic reported that the previously-approved reverse split of its stock has been implemented and that its shares are trading under the temporary symbol TBIOD.
About Transgenomic
Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in oncology and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCR, which enables use of liquid biopsies for mutation detection. The company also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes.
About Precipio Diagnostics
Precipio Diagnostics has built a platform to harness the intellect, expertise and technology developed within academia, delivering quality diagnostic information to physicians and patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, and its experience delivering quality service, Precipio Diagnostics offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, visit precipiodx.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements,” which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets, expectations regarding new clients, projects and prospects, and ICP’s ability to accelerate the Company’s growth and generate revenue. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170616005138/en/
Copyright © 2017 Businesswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Substantial Expansion in Cannabis Operations and Grow Facilities in North America Leading to Increased Production and Revenues
June 20, 2017
http://www.otcmarkets.com/stock/CNBX/news